SK36895A3 - Use of hyaluronic acid and forms to prevent arterial restenosis - Google Patents

Use of hyaluronic acid and forms to prevent arterial restenosis Download PDF

Info

Publication number
SK36895A3
SK36895A3 SK368-95A SK36895A SK36895A3 SK 36895 A3 SK36895 A3 SK 36895A3 SK 36895 A SK36895 A SK 36895A SK 36895 A3 SK36895 A3 SK 36895A3
Authority
SK
Slovakia
Prior art keywords
hyaluronic acid
rhamm
pharmaceutical composition
amount
component
Prior art date
Application number
SK368-95A
Other languages
English (en)
Slovak (sk)
Inventor
Rudolf E Falk
Samuel S Asculai
Eva A Turley
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Priority claimed from PCT/CA1993/000388 external-priority patent/WO1994007505A1/en
Publication of SK36895A3 publication Critical patent/SK36895A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
SK368-95A 1992-09-25 1993-09-22 Use of hyaluronic acid and forms to prevent arterial restenosis SK36895A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002079205A CA2079205C (en) 1992-09-25 1992-09-25 Use of hyaluronic acid and forms to prevent arterial restenosis
PCT/CA1993/000388 WO1994007505A1 (en) 1991-07-03 1993-09-22 Use of hyaluronic acid and forms to prevent arterial restenosis

Publications (1)

Publication Number Publication Date
SK36895A3 true SK36895A3 (en) 1997-03-05

Family

ID=4150463

Family Applications (1)

Application Number Title Priority Date Filing Date
SK368-95A SK36895A3 (en) 1992-09-25 1993-09-22 Use of hyaluronic acid and forms to prevent arterial restenosis

Country Status (26)

Country Link
EP (1) EP0661981B1 (cs)
JP (1) JP3742955B2 (cs)
CN (1) CN1057908C (cs)
AP (1) AP448A (cs)
AT (1) ATE141054T1 (cs)
AU (1) AU670117B2 (cs)
BR (1) BR9307221A (cs)
CA (1) CA2079205C (cs)
CZ (1) CZ288986B6 (cs)
DE (1) DE69303931T2 (cs)
DK (1) DK0661981T3 (cs)
ES (1) ES2091031T3 (cs)
GR (1) GR3021171T3 (cs)
HK (1) HK35397A (cs)
HU (2) HU227067B1 (cs)
IL (1) IL107087A0 (cs)
IN (1) IN181289B (cs)
MD (1) MD960294A (cs)
MX (1) MX9305887A (cs)
NO (1) NO309457B1 (cs)
NZ (1) NZ255978A (cs)
PL (1) PL308201A1 (cs)
SG (1) SG48845A1 (cs)
SK (1) SK36895A3 (cs)
TW (1) TW271401B (cs)
ZA (1) ZA937068B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP1005874B1 (en) * 1997-08-22 2005-05-18 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid gel, process for producing the same and medical material containing the same
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease

Also Published As

Publication number Publication date
HUT73637A (en) 1996-08-28
CN1057908C (zh) 2000-11-01
SG48845A1 (en) 1998-05-18
HU227067B1 (en) 2010-06-28
CZ288986B6 (cs) 2001-10-17
HU211698A9 (en) 1995-12-28
JP3742955B2 (ja) 2006-02-08
DK0661981T3 (da) 1996-12-23
AP448A (en) 1996-01-18
HK35397A (en) 1997-03-27
IL107087A0 (en) 1993-12-28
BR9307221A (pt) 1999-07-27
MD960294A (ro) 1997-10-31
AP9300568A0 (en) 1993-10-31
DE69303931T2 (de) 1997-01-09
AU4812693A (en) 1994-04-26
TW271401B (cs) 1996-03-01
EP0661981A1 (en) 1995-07-12
JPH08506797A (ja) 1996-07-23
NO951122D0 (no) 1995-03-23
NO309457B1 (no) 2001-02-05
AU670117B2 (en) 1996-07-04
ZA937068B (en) 1994-04-18
EP0661981B1 (en) 1996-08-07
ATE141054T1 (de) 1996-08-15
CZ66295A3 (en) 1996-02-14
NZ255978A (en) 1997-02-24
CA2079205A1 (en) 1994-03-26
IN181289B (cs) 1998-05-02
CA2079205C (en) 1998-02-10
PL308201A1 (en) 1995-07-24
MX9305887A (es) 1994-05-31
CN1092654A (zh) 1994-09-28
HU9500857D0 (en) 1995-05-29
ES2091031T3 (es) 1996-10-16
GR3021171T3 (en) 1996-12-31
DE69303931D1 (de) 1996-09-12
NO951122L (no) 1995-03-23

Similar Documents

Publication Publication Date Title
US5990095A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US6022866A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US20230279048A1 (en) Compositions containing hc-ha/ptx3 complexes and methods of use thereof
WO1994007505A1 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US20070141101A1 (en) Method for stimulating angiogenesis and wound healing
CA2573720A1 (en) Netrin-related compositions and uses
JP4307561B2 (ja) 創傷の治癒
JP6903640B2 (ja) てんかんの治療方法
WO1995026193A1 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
EP2185581B1 (en) Methods and compositions useful in the treatment of mucositis
WO2016065083A1 (en) Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
SK36895A3 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
SK126595A3 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
US20180280478A1 (en) Activators of cxcr3 for the treatment of angiopathies of the eye
JPH10506884A (ja) マクロファージ浸潤に関連する病気あるいは容体、特に脳卒中、心筋梗塞の治療
US20160113936A1 (en) Methods for modulating monocyte function
CA2120045C (en) Use of hyaluronic acid and forms to prevent arterial restenosis
AU702929B2 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US20110027884A1 (en) Combination of insulin and ascorbate to enhance wound healing
JP2018536642A (ja) 椎間関節の疾患の処置のための、ヒアルロン酸を含む架橋された血清アルブミン
NZ299942A (en) Use of hyaluronic acid (or fragments thereof) to prevent narrowing of tubular walls in an animal (typically arterial restenosis)
KR102118116B1 (ko) Foxp3 또는 이를 코딩하는 유전자를 포함하는 나노입자 및 이의 용도
Cuevas et al. Suppression of acidic fibroblast growth factordependent angiogenesis. by the antigrowth activity of 1, 3, 6-naphthalenetrisulfonate
US20240101621A1 (en) Molecular superstructure and methods of use thereof
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy